LLM 2021 | The role of transplant in MCL in the era of cellular therapy
Natalie Grover
• 15 Oct 2021
Natalie Grover, MD, UNC School of Medicine, Chapel Hill, NC, comments that allogeneic transplant still has a role in mantle cell lymphoma (MCL) because there are not enough long-term data on the duration of the remission after CAR T-cell treatment. In young, fit patients, the longer follow-up after treatment shows durable remissions and supports the use of allogeneic transplant as an option, but preferably after CAR T-cell treatment relapse since its results are promising, and the toxicity rates are lower. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.
Disclosures
Consulting: Tessa and Novartis
Advisory board: ADC therapeutics and Kite
Research funding: Genentech
